B-Cell---Burkitt's like
Showing 1 - 25 of >10,000
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
Diffuse Large B Cell Lymphoma Trial in Suzhou (Rituximab, Orelabrutinib, Pomalidomide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +4 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))
Not yet recruiting
- Leukemia
- +12 more
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- (no location specified)
Mar 20, 2023
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt
Not yet recruiting
- Relapsed/Refractory Waldenstrom Macroglobulinemia
- +3 more
- Brexucabtagene Autoleucel
- +2 more
- (no location specified)
Sep 8, 2022
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Recruiting
- Diffuse Large Cell Lymphoma
- +4 more
- Vincristine
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma Trial in United States (Rituximab, IT Cytarabine)
Completed
- Diffuse Large Cell Lymphoma
- +2 more
- Rituximab
- IT Cytarabine
-
Buffalo, New York
- +4 more
Oct 29, 2021
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Wenzhou, Zhejiang, ChinaFirst Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Ibrutinib 420 mg)
Not yet recruiting
- Autoimmune Hemolytic Anemia
- +3 more
- Ibrutinib 420 mg
- (no location specified)
Jan 12, 2023
Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma Trial in United Kingdom (AZD3965)
Completed
- Adult Solid Tumor
- +2 more
-
Sutton, London, United Kingdom
- +6 more
Feb 10, 2022
Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma Trial in Mwanza (mNavigator)
Active, not recruiting
- Burkitt Lymphoma
- +2 more
- mNavigator
-
Mwanza, Lake Zone, TanzaniaBugando Medical Centre
Mar 7, 2022
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,
Recruiting
- Refractory Non-Hodgkin Lymphoma
- +8 more
- Fludarabine
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 2, 2022
DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Orelabrutinib
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 10, 2022
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States
Recruiting
- Relapsed/Refractory B-cell Lymphomas
- +11 more
- CLBR001 and SWI019
-
Duarte, California
- +7 more
Jul 26, 2022
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,
Not yet recruiting
- Acute Myelogenous Leukemia
- +17 more
- Peripheral Blood Stem Cell Transplant
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Mar 27, 2023
High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)
Not yet recruiting
- High-grade B-cell Lymphoma
- +8 more
- Sepantronium Bromide
-
Busan, Korea, Republic of
- +5 more
Feb 27, 2022